(EXEL:Consolidated Issue Listed on NASDAQ Global Select )
Stelios Papadopoulos Ph.D.
Co-Founder, Chairman and Member of Audit Committee, Exelixis, Inc.
|Age||Total Calculated Compensation||This person is connected to 100 board members in 10 different organizations across 13 different industries.|
See Board Relationships
Dr. Stelios Papadopoulos, Ph.D. served as Managing Director of Life Sciences Investment Banking division at SG Cowen Securities Corp until August 2006. In 1987, Dr. Papadopoulos served as the Vice President at the Equity Research Department at Drexel Burnham Lambert, covering the biotechnology industry. Dr. Papadopoulos served as Managing Director of Cowen and Company, LLC. He is a private biotechnology investor. His career in biopharmaceuticals spans more than two decades. ...
210 East Grand AvenuePhone: 650-837-7000
South San Francisco, California 94080
Board Members Memberships*
Co-Founder and Director
Former Vice Chairman and Managing Director
Co-Founder, Chairman and Member of Audit Committee
Former Co-Founder, Chairman, Chairman of Corporate Governance & Nominating Committee and Member of Compensation Committee
Director, Chairman of Nominating & Governance Committee and Member of Compensation Committee
Chairman, Member of Science & Technology Committee, Member of Audit Committee and Member of Finance Committee
Chairman, Chairman of Nominating & Corporate Governance Committee and Member of Audit Committee
New York University
New York University
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Ron Squarer BSc (Biochemistry), MBA||Chief Executive Officer and Director|
Array BioPharma, Inc.
|James A. Bianco M.D.||Principal Founder, Chief Executive Officer, President, Executive Director, Member of Scientific Advisory Board and Member of Executive Committee|
CTI BioPharma Corp.
|Ali Fattaey Ph.D.||Chief Executive Officer, President and Director|
|Robert I. Blum||Chief Executive Officer, President, Director and Chief Executive of the Biopharmaceutical Concern|
|James M. Gower||Chairman, Chief Executive Officer and Member of Finance Committee|
Rigel Pharmaceuticals, Inc.
|$695.1K||Compensation as of Fiscal Year 2014.|